%0 Journal Article
%T ¡®Les liaisons dangereuses¡¯: Hepatitis C, Rituximab and B-cell non-Hodgkin¡¯s lymphomas
%A Massimo Marignani
%A Michela di Fonzo
%A Paola Begini
%A Elia Gigante
%J World Journal of Gastrointestinal Pharmacology and Therapeutics
%D 2012
%I Baishideng Publishing Group Co. Limited
%R 10.4292/wjgpt.v3.i2.21
%X Rituximab has provided a revolutionary contribution to the treatment of B-cell non-Hodgkin¡¯s lymphomas (NHL). A high prevalence of hepatitis C virus (HCV) infection has been described in B-cell NHL patients. Cases of liver dysfunction in HCV-positive patients have been reported with Rituximab-containing regimens. In this paper we review the recent data regarding the effects of Rituximab in NHL patients with HCV infection. We also added a section devoted to improving communication between oncohaematologists and hepatologists. Furthermore, we propose a common methodological ground to study hepatic toxicity emerging during chemotherapy.
%K Rituximab
%K B-cell non-Hodgkin¡¯s lymphoma
%K Hepatitis C virus
%K Immunochemotherapy
%K Methodology
%U http://www.wjgnet.com/2150-5349/full/v3/i2/21.htm